Restatement of Previously Issued Financial Statements (Tables)

12 Months Ended

Sep. 30, 2025

Restatement of Previously Issued Financial Statements [Abstract]

Schedule of Restated Audited Consolidated Statement of Operations

Restated Audited Consolidated Statement of Operations – Fiscal Year Ended September 30, 2025

Line item		As Previously Reported on 10-K				Restatement Adjustment				ID				As Restated
Cost of revenue, net			1,756				1,479				5,8				3,235
Gross profit			3,289				(1,479	)			*				1,810
Research and development			2,432				870				6				3,302
Sales and marketing			1,262				(521	)			5				741
General and administrative			17,539				(2,572	)			5,6,7,9				14,967
Total operating expenses			21,233				(2,223	)			*				19,010
Income (loss) from operations			(17,944	)			744				*				(17,200	)
Other income (loss)			-				(34,172	)			2,3				(34,172	)
Total other expense			2,094				(34,172	)			*				(32,078	)
Loss before income tax expense			(15,850	)			(33,428	)			*				(49,278	)
Income tax benefit / (expense)			(12	)			108				10				96
Consolidated net loss			(15,862	)			(33,320	)			*				(49,182	)
Net loss attributable to common stockholders			(15,754	)			(33,320	)			*				(49,074	)
Basic and diluted net loss per share of common stock		$	(0.13	)										$	(0.40	)

Restated Audited Consolidated Statement of Operations – Fiscal Year Ended September 30, 2024

Line item		As Previously Reported on 10-K				Restatement Adjustment				ID				As Restated
Cost of revenue, net			1,520				17				5,8				1,537
Gross profit			2,720				(17	)			*				2,703
Research and development			2,021				614				6				2,635
General and administrative			6,457				76				5,6,7				6,533
Total operating expenses			9,793				690				*				10,483
Income (loss) from operations			(7,073	)			(707	)			*				(7,780	)
Other income (loss)			-				7,587				2,3,4				7,587
Total other expense			(749	)			7,587				*				6,838
Loss before income tax expense			(7,822	)			6,880				*				(942	)
Income tax benefit / (expense)			(318	)			(108	)			10				(426	)
Consolidated net loss			(8,140	)			6,772				*				(1,368	)
Net loss attributable to common stockholders			(8,140	)			6,772				*				(1,368	)
Basic and diluted net loss per share of common stock		$	(0.12	)										$	(0.02	)

Schedule of Restated Audited Consolidated Statement of Equity

Restated Audited Consolidated Statement of Equity – Fiscal Year Ended September 30, 2025

Line item		As Previously Reported on 10-K				Restatement Adjustment				ID				As Restated
Additional paid-in capital, issuance of shares upon exercise of warrants for cash			16,265				22,168				2,3				38,433
Additional paid-in capital			293,156				7,545				*				300,701
Net loss attributable to common stockholders			(15,754	)			(33,319	)			*				(49,073	)
Retained earnings			(23,693	)			(26,548	)			*				(50,241	)
Total stockholders’ equity			269,833				(19,003	)			*				250,830

Restated Audited Consolidated Statement of Equity – Fiscal Year Ended September 30, 2024

Line item		As Previously Reported on 10-K				Restatement Adjustment				ID				As Restated
Issuance of common shares for loan settlement			3,383				(2,083	)			4				1,300
Additional paid-in capital, issuance of shares upon exercise of warrants for cash			-				2,937				2,3				2,937
Issuance of new shares for cash			30,124				(15,487	)			2,3				14,637
Additional paid-in capital			49,667				(14,623	)			*				35,044
Net loss attributable to common stockholders			(8,140	)			6,772				*				(1,368	)
Retained earnings			(7,939	)			6,772				*				(1,167	)
Total stockholders’ equity			41,738				(7,851	)			*				33,887

Schedule of Restated Audited Consolidated Statement of Cash Flows

Restated Audited Consolidated Statement of Cash Flows – Fiscal Year Ended September 30, 2025

Line item		As Previously Reported on 10-K				Restatement Adjustment				ID				As Restated
Consolidated net loss			(15,754	)			(33,428	)			*				(49,182	)
Depreciation and amortization			2,319				(932	)			7,9				1,387
Change in fair value of warrant liability			-				34,172				2,3				34,172
Issuance costs related to warrants			-				189				1				189
Inventory			(232	)			136				8				(96	)
Accounts receivable			(421	)			(1	)			*				(422	)
Non-operating losses			(108	)			108				*				-
Deferred income taxes			-				(108	)			10				(108	)
Change in operating lease liabilities			225				(4	)			*				221
Net cash provided by operating activities			(9,043	)			132				*				(8,911	)
Purchase of PPE			(5,009	)			(135	)			8				(5,144	)
Purchase of intangible assets			(591	)			1				*				(590	)
Purchase of short-term investments			(41,975	)			(8,053	)			11				(50,028	)
Net cash used in investing activities			(47,996	)			(8,187	)			*				(56,183	)
Net change in cash and cash equivalents			179,063				(8,055	)			*				171,008
Cash, cash equivalents, and restricted cash at end of period			193,629				(8,055	)			*				185,574

Restated Audited Consolidated Statement of Cash Flows – Fiscal Year Ended September 30, 2024

Line item		As Previously Reported on 10-K				Restatement Adjustment				ID				As Restated
Consolidated net loss			(8,140	)			6,772				*				(1,368	)
Change in fair value of warrant liability			-				(5,185	)			2,3				(5,185	)
Gain on standby equity purchase agreement			-				(2,402	)			4				(2,402	)
Issuance costs related to warrants			-				371				3				371
Issuance costs related to SEPA			-				319				4				319
Amortization of notes payable discount			-				120				4				120
Inventory			(326	)			119				8				(207	)
Accrued expenses and other payable			38				(120	)			4				(82	)
Deferred income taxes			518				108				10				626
Depreciation and amortization			81				17				7,9				98
Net cash provided by operating activities			(5,060	)			119				*				(4,941	)
Purchase of PPE			(725	)			(119	)			8				(844	)
Purchase of intangible assets			(5,470	)			(1	)			9				(5,471	)
Net cash used in investing activities			(22,731	)			(120	)			*				(22,851	)
Loan settlement			3,383				2				4				3,385
Net cash used in financing activities			41,923				2				*				41,925
Net change in cash and cash equivalents			14,132				1				*				14,133

*	Represents the downstream effects of the identified restatement adjustments and other individually immaterial changes.